ChemicalBook
Chinese Japanese Germany Korea

Torezolid

Novel antibacterial drugs Indications State of Intellectual Property
Torezolid
Torezolid structure
CAS No.
856866-72-3
Chemical Name:
Torezolid
Synonyms
CS-1826;DA 7157;DA-7157;Tedizolid;Torezolid;Torezolid-21;Tedizolidted;Torezolid (TR-701;Tedizolid (TR 700;Tedizolid (TR-701)
CBNumber:
CB02484972
Molecular Formula:
C17H15FN6O3
Formula Weight:
370.34
MOL File:
856866-72-3.mol

Torezolid Properties

Melting point:
201 °C
Boiling point:
614.5±65.0 °C(Predicted)
Density 
1.57
pka
14.05±0.10(Predicted)
CAS DataBase Reference
856866-72-3
FDA UNII
97HLQ82NGL
SAFETY
  • Risk and Safety Statements
HS Code  29339900

Torezolid Chemical Properties,Uses,Production

Novel antibacterial drugs

Tedizolid belongs to the second generation oxazolidinone antibiotics, being an analog of linezolid as well as a kind of protein synthesis inhibitors, acting on the bacterial ribosomal 50S subunit and causing inhibition of bacterial protein synthesis. Compared with linezolid, the efficacy of the two is basically the same, but linezolid required to be taken for 2 times a day and for 10 continuous days while Tedizolid only takes 1 time daily and continuous taking for 6 days.
On June 20, 2014, the US FDA had approved a new antimicrobial drug Tedizolid (trade name: Sivextro) for the treatment of skin infections in adult patients. Sivextro is approved for the treatment of acute bacterial skin and skin infections caused by certain sensitive bacteria such as Staphylococcus aureus (including methicillin-resistant strains and methicillin-sensitive strains), various streptococci and Enterococcus faecalis (ABSSSI). Sivextro is administered intravenously and orally.
Tedizolid phosphate is a second-generation oxazolidinone antibiotic developed by Dong-A Pharmaceutical, licensed to Cubist Pharmaceuticals and Bayer for commercial development.
Sivextro is designed for the treatment of serious or life-threatening infections, and its listing applications are eligible for Qualified Infectious Disease Products (QIDP) and have obtained the approve of FDA for accelerated review. Sivextro's QIDP eligibility gives the drug exclusive five-year market exclusivity, in addition to its market exclusivity under the Food, Drug, and Cosmetic Act.
The safety and efficacy of Sivextro were evaluated in two clinical trials involving 1315 ABSSSI adult patients. Subjects were randomized to Sivextro or another antibiotic linezolid approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The results showed that its clinical efficacy is equivalent to linezolid. However, it will cause less gastrointestinal adverse reactions and thrombocytopenia adverse reactions than linezolid. The incidence of drug resistance is also lower. Tedizolid has been shown to be more tolerant than vancomycin.
The most common side effects identified in clinical trials include nausea, headache, diarrhea, vomiting and dizziness. The safety and efficacy of Sivextro have not been evaluated in patients with reduced white blood cell levels (neutropenia), so alternative therapies should be considered for these patients. Sivextro is marketed by Cubist Pharmaceuticals, Inc., based in Lexington, Massachusetts.
Status of intellectual property: Compound patent ZL200480037612.2, protection period 2024.12.17 expires.
This information was edited by Xiao Nan from Chemicalbook (2015-08-14).

Indications

Tedizolid phosphate is an oxazolidinone compound used in the treatment of acute bacterial skin and skin structure infections caused by the following gram-positive bacteria-sensitive strains: Staphylococcus aureus (including Methicillin-resistant and methicillin-susceptible strains), pyogenic streptococci, Streptococcus lactis, Streptococcus angustifolia (including Angina, Streptococcus intermedius and Streptococcus constellation), and Enterococcus faecalis.

State of Intellectual Property

(A) Administrative protection, new drug protection and new drug monitoring period
On August 9, 2013, Bayer Pharmaceuticals has filed a new drug application with CFDA.
(B) Domestic patent
1. Patented compounds
East Asia Pharmaceutical has applied for the compound patent in China under the application number is ZL200480037612.2. The date of application is December 17, 2004; the protection period will expire at 2024.12.17. Three subsequent divisional applications were further filed with the application numbers being 201010508824.1 (preparation), 201110304983.4, 201210155386.4.
On October 9, 2009, the Teresius Therapeutics Company has applied for a preparation method patent with the patent number of 200980140144.4.
2. Crystal patent
On February 3, 2010, Teulius Therapeutics applied for a crystalline form patent of free acid with the application number of 201080014363.0. Form I of the disclosed free acid has the advantage that it is more stable than the disodium salt and has no moisture absorption.
3. Formulation Composition Patents
The above-mentioned patent 200480037612.2 and its divisional application patent have disclosed the Tedizolid powder, tablet, capsule and injection.
The above-mentioned patent 201080014363.0 have disclosed the prescription of Tedizolid tablets and freeze-dried preparations.

Uses

Tedizolid, known as TR-700, is an oral and i.v administered intracellular antibacterial drug.

Definition

ChEBI: A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5 It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and meth cillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.

Torezolid Preparation Products And Raw materials

Raw materials

Preparation Products


Torezolid Suppliers

Global( 193)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Henan DaKen Chemical CO.,LTD.
+86-371-66670886
info@dakenchem.com China 21032 58
Shanghai Bojing Chemical Co.,Ltd.
+86-21-37122233
+86-21-37127788 Candy@bj-chem.com CHINA 497 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22607 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070
product@chemlin.com.cn CHINA 3013 60
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 26734 60
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 29961 58
NINGBO INNO PHARMCHEM CO., LTD.
13867897135
sales@nbinno.com CHINA 925 58
Zhejiang ZETian Fine Chemicals Co. LTD
18957127338
stella@zetchem.com CHINA 2007 58
Changzhou Ansciep Chemical Co., Ltd.
+86 519 86305871
+86 519 86305879 sales@ansciepchem.com CHINA 4242 58
Hebei Guanlang Biotechnology Co., Ltd.
+8619930503282
sales3@crovellbio.com China 5361 58

View Lastest Price from Torezolid manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2021-08-07 Torezolid
856866-72-3
US $10.00 / KG 1KG 99% 10 mt Hebei Guanlang Biotechnology Co., Ltd.
2021-07-17 Torezolid USP/EP/BP
856866-72-3
US $1.10 / g 1g 99.9% 100 Tons Min Dideu Industries Group Limited
2021-07-13 Tedizolid
856866-72-3
US $15.00-10.00 / KG 1KG 99%+ HPLC Monthly supply of 1 ton Zhuozhou Wenxi import and Export Co., Ltd

856866-72-3(Torezolid)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved